IPdR: A novel oral radiosensitizer

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1415-1424

  Saif, Muhammad Wasif ^a   Berk, Greg ^b   Cheng, Yung Chi ^a   Kinsella, Timothy James ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hana Biosciences   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Aldehyde oxidase; IPdR; IUdR; Radiosensitizer; Radiotherapy

Indexed keywords

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; ALDEHYDE OXIDASE; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IDOXURIDINE; IRINOTECAN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; RADIOSENSITIZING AGENT; THYMIDINE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; 1 (2 DEOXY BETA RIBOFURANOSYL) 5 IODO 2 PYRIMIDINONE; 1-(2-DEOXY-BETA-RIBOFURANOSYL)-5-IODO-2-PYRIMIDINONE; NEW DRUG; PYRIMIDINE NUCLEOSIDE;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INACTIVATION; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; LIVER METASTASIS; MISMATCH REPAIR; MONOTHERAPY; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PANCREAS TUMOR; RADIOSENSITIZATION; RECTUM TUMOR; REVIEW; SARCOMA; SINGLE DRUG DOSE; TUMOR XENOGRAFT; VOMITING; WEIGHT REDUCTION; ANIMAL; DRUG SCREENING; METHODOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548578911     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1415     Document Type: Review

References (45)

1. KINSELLA TJ: An approach to the radiosensitization of human tumors. Cancer J. Sci. Am. (1996) 2:184-193.
2. MCGINN CJ, SHEWACH DS, LAWRENCE TS: Radiosensitizing nucleosides. J. Natl. Cancer Inst. (1996) 88:1193-1203.
3. MILLER EM, FOWLER JF, KINSELLA TJ: Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat. Res. (1992) 131:81-89.
4. LAWRENCE TS, DAVIS MA, MAYBAUM J, STETSON PL, ENSMINGER WD: The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int. J. Radiat. Oncol Biol. Phys. (1990) 18:1393-1398.
5. KINSELLA TJ, DOBSON PP, MITCHELL JB, FORNACE AJ: Enhancement of X-ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int. J. Radiat Oncol. Biol Phys. (1987) 13:733-739.
6. FORNACE AJ, DOBSON PP, KINSELLA TJ: Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int. J. Radiat. Oncol. Biol. Phys. (1990) 18:873-878.
7. LAWRENCE TS, DAVIS MA, MAYBAUM J, STETSON PL, ENSMINGER. WD: The effect of single versus double stranded substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res. (1991) 123:192-198.
8. WANG Y, ILIAKIS G: Effects of 5′-iododeoxyuridine on the repair of radiation induced potentially lethal damage, interphase chromatin breaks, and DNA double strand breaks in Chinese hamster ovary cells. Int. J. Radiat. Oncol. Biol. Phys. (1992) 23:353-360.
9. CHANG AI, COLLINS JM, SPETH PAJ et al.: A Phase I study of intra-arterial iododeoxyuridine in patients with colorectal liver metastases. J. Clin. Oncol. (1989) 6:718-724.
10. KNOL J, WALKER S, ROBERTSON J et al.: Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patient receiving a 7-day hepatic arterial infusion. Cancer Res. (1995) 55:3687-3691.
11. SPETH PAJ, KINSELLA TJ, BELANGER K et al.: Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a Phase I and clinical pharmacological study. Cancer Res. (1988) 48:2933-2937.
12. MCGINN CJ, KUNUGI KA, TUTSCH KD et al.: Leucovorin modulation of iododeoxyuridine radiosensitization: a Phase I study. Clin. Cancer Res. (1996) 2:1299-1305.
13. KINSELLA TJ, KUNUGI KA, VIELHUBER KA, FOWLER J, FITZSIMMONS M, COLLINS JM: Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) as a prodrug for IUdR-mediated tumor radiosensitization in mouse and human tissues. Clin. Cancer Res. (1998) 4:99-109.
14. KINSELLA TJ, VIELHUBER KA, KUNUGI KA, SCHUPP J, DAVIS TW, SANDS H: Pre-clinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) as a prodrug for IUdR-radiosensitization in U251 human glioblastoma xenografts. Clin. Cancer Res. (2000) 6:1468-1475.
15. SEO Y, YAN T, SCHUPP J, RADIVOYEVITCH T, KINSELLA T: Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as a in vivo radiosensitizer in U251 human glioblastoma xenografts. Clin. Cancer Res. (2005) 11:7499-7507.
16. EFANGE SMN, ALESSI EM, SHIH HC, CHENG Y-C, BARDOS TJ: Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone-2′-deoxyribonucleosides. J. Med. Chem. (1985) 28:904-910.
17. LEWANDOWSKI GA, GRILL SP, FISHER MH et al.: Anti-herpes simplex virus activity of 5-substituted 2-pyrimidinone nucleosides. Antimicrob. Agents Chemother. (1989) 33:340-344.
18. LEWANDOWSKI GA, CHENG Y-C: Mechanism and mode of action of 5-iodo-2-pyrimidinone 2′-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells. Mol. Pharmacol. (1990) 39:27-33.
19. CHANG C-N, DOONG S-L, CHENG Y-C: Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase: implications in hepatotropic drug design. Biochem. Pharmacol. (1992) 43:2269-2273.
20. KINSELLA TJ, KUNUGI KA, VIELHUBER KA, MCCULLOCH W, LIU S-H, CHENG Y-C: An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res. (1994) 54:2695-2700.
21. SEO Y, YAN T, SCHUPP JE, COLUSSI V, TAYLOR KL, KINSELLA TJ: Differential radiosensitization in mismatch repair proficient and deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose. Clin. Cancer Res. (2004) 10:7520-7528.
22. KINSELLA TJ, KINSELLA MT, HONG SW, JOHNSON JP, BURBACK B, TOSCA PJ: Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidimone-2-deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on initial Phase I trial design of IpdR-mediated radiosensitization. Cancer Chemother. Pharmacol. (2007) (In Press).
23. KINSELLA TJ, SCHUPP JE, DAVIS TW et al.: Pre-clinical studies of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2′-deoxyribose (IPdR) as a radiosensitizing prodrug in two, non-rodent animal species: Implications for Phase I study design. Clin. Cancer Res. (2000) 6:3670-3679.
24. SCHULTZ C, GAFFNEY D, LINDSTROM M, KINSELLA TJ: Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J. Sci. Am. (1995) 1:151-161.
25. URTASUN R, KINSELLA T, FARNAM N, DELROWE J, LESTER S, FULTON D: Survival improvement in anaplastic astrocytoma combing external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study. Int, J. Radiat Oncol. Biol. Phys. (1996) 35:1163-1167.
26. PRADOS M, SCOTT C, ROTMAN M et al.: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology group (NCOG) and Radiation Therapy Oncology Group Trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40:653-659.
27. EISBRUCH A, ROBERTSON JM, JOHNSTON CM et al.: Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a Phase I and drug incorporation study. J. Clin. Oncol. (1999) 17:31-40.
28. EPSTEIN AH, LEBOVICS RS, GOFFMAN T et al.: Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J. Natl. Cancer Inst. (1994) 86:1775-1780.
29. TOCHNER Z, KINSELLA TJ, ROWLAND J, GLATSTEIN E: Treatment of unresectable sarcomas of adults with hyperfractionated irradiation and iododeoxyuridine. Br. J. Radiol. (1989) 19:107-111.
30. SONDAK VK, ROBERTSON JM, SUSSMAN JJ, SARAN PA, CHANG AE, LAWRENCE TS: Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann. Surg. Oncol. (1998) 5:106-112.
31. LAWRENCE TS, DAVIS MA, MAYBAUM J: Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int. J. Radiat. Oncol. Biol. Phys. (1994) 29(3):519-523.
32. BUCHHOLZ DJ, LEPEK KJ, RICH TA, MURRAY D: 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. (1995) 32(4):1053-1058.
33. NAKAMOTO S, MITSUHASHI N, TAKAHASHI T, SAKURAI H, NIIBE H: An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Int. J. Radiat. Biol. (1996) 70(6):747-753.
34. DOUPLE EB, RICHMOND RC, O'HARA JA, COUGHLIN CT: Carboplatin as a potentiator of radiation therapy. Cancer Treat. Rev. (1985) 12(Suppl. A):111-124.
35. RAVE-FRÄNK M, SCHMIDBERGER H, CHRISTIANSEN H, BOLL C, LEHMANN J, WEISS E: Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells. Int. J. Radiat. Biol. (2007) 83(1):41-47.
36. GRAU C, OVERGAARD J: Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. Int. J. Radiat. Oncol. Biol. Phys. (1991) 20(2):265-269.
37. TOMA S, PALUMBO R, VINCENTE M et al.: Concomitant doxorubicin (DOXO) by continuous infusion (CI) and radiotherapy (RT) at low doses in locally advanced and/or metastatic soft tissue sarcomas (STS): long-term results of a Phase II study. Proc. Am. Sec. Clin. Oncol. (1995) 14:520 (Abstract).
38. VAN RENSBURG CE, SLABBERT JP, BOHM L: Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions. Anticancer Res. (2006) 26(1A):389-393.
39. LAMOND JP, MEHTA MP, BOOTHMAN DA: The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neurooncol. (1996) 30(1):1-6.
40. FUKUOKA K, ARIOKA H, IWAMOTO Y et al.: Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer (2001) 34(3):451-460.
41. TISHLER RB, SCHIFF PB, GEARD CR, HALL EJ: Taxol: a novel radiation sensitizer. Int J. Radiat. Oncol. Biol. Phys. (1992) 22(3):613-617.
42. MILAS L, FUJII T, HUNTER N et al.: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. (1999) 59(1):107-114.
43. MOSE S, KARAPETIAN M, JÜLING-POHLIT L et al.: Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res. (2000) 20(1A):401-405.
44. BLANQUICETT C, SAIF MW, BUCHSBAUM DJ et al.: Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin. Cancer Res. (2005) 11(24 Part 1):8773-8781.
45. SAIF MW, ELOUBEIDI MA, RUSSO S et al.: Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J. Clin. Oncol. (2005) 23(34):8679-8687.